Preterm birth is defined as a birth prior to 37 completed Background: weeks' gestation. It affects more than 10% of all births worldwide, and is the leading cause of neonatal mortality in non-anomalous newborns. Even if the preterm newborn survives, there is an increased risk of lifelong morbidity.
Introduction Definition and significance of preterm birth Preterm birth (PTB), defined as birth prior to 37 completed weeks' gestation, is a major public health problem that affects more than 10% of all births worldwide 1, 2 . Globally, an estimated 15 million babies are born premature each year 1, 2 . Despite substantial public health efforts over the past several decades, the U.S. PTB rate remained at 11.72% in 2011 3, 4 .
PTB is the leading cause of neonatal mortality in non-anomalous newborns 1, 3, 5, 6 . It is also associated with a broad spectrum of lifelong morbidity in surviving preterm infants, including neuro-developmental delay, cerebral palsy, blindness, deafness, and chronic lung disease [7] [8] [9] .
Definition of spontaneous preterm birth Some PTBs are iatrogenic and can be attributed to obstetric intervention aimed at reducing maternal and/or fetal risk. The remaining PTBs are known as spontaneous PTB (SPTB) and are the focus of research efforts to identify genetic and environmental risk factors. Although SPTB is a pressing health issue, the incomplete understanding of its biology has inhibited development of effective prevention and treatment strategies.
Genetics of spontaneous preterm birth
The etiology of SPTB is complex and multifactorial 9-12 , although genetic factors are important contributors [9] [10] [11] [12] [13] [14] . In addition, PTB prevalence varies among different population groups [15] [16] [17] [18] [19] . African-American ancestry is consistently associated with an increased PTB risk, even after adjusting for epidemiologic risk factors, such as income, education, lack of prenatal care, and other socioeconomic factors 10,20,21 .
A candidate gene approach has identified polymorphisms in genes that encode the progesterone receptor, tumor necrosis factor alpha, interleukins 4, 6, and 10, and mannose-binding lectin [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] , that are mildly to modestly associated with SPTB. However, results have been inconsistent 29, [34] [35] [36] .
Our genome-wide approach for spontaneous preterm birth Here, we employed an unbiased, genome-wide approach to search for possible candidate genes associated with SPTB. Genome-wide association studies (GWAS), or whole genome association studies, are a commonly used genetic approach to study a disease or a trait. GWAS compares thousands or even millions of common genetic markers, mainly single nucleotide polymorphisms (SNPs), across individuals with a disease or trait status. There are 1,688 publications identifying 11,299 SNPs that are significant for diseases or traits in 17 different categories 37, 38 . We obtained the SPTB phenotype and genotype data deposited in the National Center for Biotechnology Information (NCBI) Genotypes and Phenotypes Database (dbGaP) 39, 40 , study accession phs000103.v1.p1, to perform a GWAS to explore genetic variants associated with SPTB.
Materials and methods

Data application and approval
We applied to and received approval from dbGaP 39,40 for access to a dataset for SPTB phenotype and genotype (study accession phs000103.v1.p1). We followed the Data Use Certification Agreement we signed during the application.
To access the data, one must apply and agree to the dbGAP terms of usage. A detailed instructions and procedures for application can be obtained at https://dbgap.ncbi.nlm.nih.gov/.
Data content
This dataset contains participants collected by the Danish National Birth Cohort (DNBC) 41 . DNBC is a prospective cohort that enrolled more than 100,000 pregnant women in the first trimester, before most adverse outcomes occurred, and therefore is free from sampling or collection bias. In this dataset, there are approximately 1000 preterm births and 1000 term births as controls. These study subjects were collected from 1997 to 2003. All are singleton gestations. Each birth has records of mother-child pairs. With the exception of 24 children with one or two grandparents from other Nordic countries, all other children in the dataset had parents and all four grandparents born in Denmark.
The case (preterm) group contains births delivered before 37 gestational weeks. The control (term) group contains births delivered at approximately 40 weeks' gestation. In both preterm and term groups, children born with any recognized congenital or genetic abnormality were excluded. Pregnancies with maternal conditions known to be associated with PTB, iatrogenic or spontaneous (placenta previa, placental abruption, hydramnios, isoimmunization, placental insufficiency, pre-eclampsia/eclampsia), were also excluded by DNBC.
The blood sample (buffy coat) was collected for each mother-child pair. Their whole genomes were genotyped on the Illumina Human660W-Quad_v1_A platform (Illumina, Inc., San Diego, California, USA), which contains more than 500,000 markers. Genotyping was performed by the Johns Hopkins University Center for Inherited Disease Research (Baltimore, Maryland, USA). Further data cleaning and harmonization were done at the GENEVA Coordinating Center at the University of Washington (Seattle, Washington, USA).
Quality control
In this study, we focused only on fetal genomes for further analysis. Individuals with missing genotypes greater than 3% were filtered out. In addition, individuals with a heterozygosity rate deviating more than 3 standard deviations were also excluded from further analysis 42 . After per-individual quality control, we also performed per-SNP filtering. The SNPs that had missing genotypes greater than 3% were excluded 42 . Those having significantly different genotype missing rate between the case and control groups were also eliminated. A conservative cut-off with p < 1×10
-5 was applied
42
. We also excluded SNPs that significantly deviated from Hardy-Weinberg equilibrium in the control group -those with p < 1×10 -5 were filtered out 42, 43 .
Data analysis
After data quality control, we performed GWAS for the fetal genomes on 22 autosomal chromosomes using the PLINK software package v1.07 44 (http://pngu.mgh.harvard.edu/purcell/plink/). The level of genome-wide significance was set at 9.18×10 -8
, corresponding to Bonferroni correction for 544,675 multiple independent tests. Quantile-quantile (QQ) plot was made using STATA Statistical Software, Release 12 45 . Manhattan plots were generated using Haploview 46 .
Results
Data overview
We started with a dataset comprised of 1,900 children. There were 31 children having a missing genotype rate greater than 3%. The average heterozygosity was 0.3238, with standard deviation of 0.0059. There were also 31 children having heterozygosity that deviated more than 3 standard deviations. In fact, there was considerable overlap when applying these two filtering criteria (Figure 1 ) -26 individuals were identified by both exclusion criteria. During per-individual quality control, a total of 36 individuals were excluded, resulting in 1864 individuals. However, 66 of them had a missing phenotype, yielding a final total of 849 cases and 949 controls (Table 1) .
Among the 560,768 markers, there were 1,933 SNPs that exceeded the missing rate threshold of 3%. There were 367 SNPs that had a significantly different missing rate between the case group and control group (P value < 1×10 ). These three criteria also identified some overlapping SNPs; a total of 2,670 SNPs were excluded using all criteria. These quality control steps left 558,098 SNPs remaining in the dataset. Of these SNPs, 544,675 of them are located on 22 autosomes, and were included in the analysis (Table 1) . (Figure 2 ) and QQ plot (Figure 3) ). 
Allelic test
We carried out GWAS for these 1,798 individuals, of which 849 are SPTB cases and 949 are term controls, over 544,675 SNPs on 22 autosomal chromosomes. An allelic test was first carried out, and no SNPs reached genome-wide significance after Bonferroni correction for multiple testing (Manhattan plot
Other genetic models
We then performed GWAS with different genetic models. We tested three classical Mendelian inheritance models here. The recessive model assumes that carrying two variant alleles is required to present a different phenotype; while in the dominant model, one variant allele is sufficient to present a different phenotype as carrying two variant alleles. The additive model assumes the heterozygotes present an intermediate phenotype between the two homozygotes and thus consider
I. Participants (Individuals)
Original dataset 1900
Per-individual quality control exclusion 36
Missing genotype rate > 3% 31
Heterozygosity > 3 sd 31
Missing phenotype 66
Remained for analysis 1,798
II. Markers (SNPs)
Original dataset 560,768
Per-marker quality control exclusion 2,670
Missing genotype rate > 3%
1,933
Missing genotype rate significantly different between case and control
367
Significantly deviate from Hardy-Weinberg equilibrium in control group
885
Not on autosomes
13,423
Remained for analysis 544,675
sd: standard deviations.
genetic models, no SNP reached genome-wide significance after Bonferroni correction for multiple testing.
Discussion
Here we describe a negative result for associations between SPTB and genetic polymorphisms of 22 autosomal chromosomes in a homogeneous European population. Myking et al. reported a GWAS focusing on the X chromosome 47 and they incorporated Danish cases and controls from DNBC 41, 47 , in addition to participants enrolled from the Norwegian Mother and Child Cohort Study (MoBa) 48 .Nevertheless, with a larger sample size (DNBC + MoBa), and fewer independent tests limited to the markers on X chromosomes, no SNP reached genome-wide significance after Bonferroni correction 47 .
One way to decrease the probability of a negative result is to increase the sample size, either by recruiting more cases and controls directly, or by combining different studies and conducting a meta-analysis 49, 50 . Instead of sequencing thousands or millions of sporadic cases plus controls, another approach is to study SPTB using a family-based design -i.e., identify high-risk pedigrees in which a genetic mutation is more likely to be present in multiple individuals. Pedigree studies have the additional advantage of reduced phenotypic heterogeneity 49 . Several loci associated with SPTB have been identified by using family-based linkage studies 51, 52 .
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Another approach is to employ whole genome or whole exome sequencing. This will help to identify rare genetic variants with potentially larger effect sizes.
Another approach that may increase statistical power is to analyze the SPTB phenotype as a quantitative trait instead of a dichotomous one. The distribution of gestational age in the population is approximately normal 53 . Therefore, to analyze SPTB as a quantitative trait (i.e., gestational age), samples should be drawn randomly from the population of newborns.
Conclusion
We found no evidence of genetic association with SPTB in Danish population using an unbiased genome-wide approach. A familybased design in a high risk pedigree, and whole genome or exome sequencing, may yield higher detection rates of both common and rare variants associated with SPTB.
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The authors talk about negative results in their GWAS. They should discuss why they did not discover any genome-wide significant SNP (lack of power?). They also need to discuss the weaknesses of this study, and what could be done in the future.
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